Home・Lista de Ações・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fechado

14.24 -4.04

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

13.97

Máximo

14.84

Indicadores-chave
By Trading Economics
Rendimento	-1.4M -14M
EPS	-0.15
Funcionários	37
EBITDA	312K -12M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+111.8% upside

Dividendos
By Acuity
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-29M 1.3B
Abertura anterior	18.28
Fecho anterior	14.24

Corvus Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de jul. de 2026, 23:56 UTC

Intel Corp shares are lower in after-hours trading, reflecting broader market pressures amid a significant decline in Japan's Nikkei 225 Index.

16 de jul. de 2026, 23:56 UTC

ETF Constituents

Macro News

iShares China Large-Cap ETF trades lower in after-market hours amid rising U.S.-Iran tensions and weakness in technology stocks, with notable declines from TCOM and LI.

16 de jul. de 2026, 23:56 UTC

ETF Constituents

Macro News

Correlated Moves

The iShares MSCI Japan ETF is lower in after-market trading, reflecting declines in the Nikkei 225 index and key holdings like SONY and NMR.

16 de jul. de 2026, 23:52 UTC

Fed Vice Chair Jefferson signals potential interest rate reassessment amid persistent inflation concerns.

16 de jul. de 2026, 23:52 UTC

Michigan Consumer Sentiment Index for July 2026 Forecasted at 51.0 Amid Mixed Confidence and Inflation Concerns Ahead of Release.

16 de jul. de 2026, 23:52 UTC

Social Media

News

Netflix Inc. shares fell in after-hours trading following Q2 results. Revenue of $12.56 billion missed expectations, and guidance for 2026 was narrowed lower.

16 de jul. de 2026, 23:52 UTC

Social Media

Correlated Moves

NVIDIA Corp shares declined in after-market hours, reflecting broader market downturn and geopolitical tensions. The stock underperformed against major tech peers during the session.

16 de jul. de 2026, 23:51 UTC

Global equity markets decline as Nikkei 225 drops 2.8%, while U.S. jobless claims fall unexpectedly and manufacturing activity surges, amid concerns over slowing retail sales and geopolitical tensions.

16 de jul. de 2026, 23:51 UTC

Mixed trading in European equities amid geopolitical tensions and mixed earnings; U.S. tech stocks decline as jobless claims fall unexpectedly.

16 de jul. de 2026, 23:51 UTC

U.S. equity markets remain flat amid geopolitical tensions and mixed economic data, with Nasdaq down 1.5% as oil prices surge above $80 per barrel.

16 de jul. de 2026, 23:51 UTC

Asia equity markets mixed as Japan's Nikkei drops 2.8% on tech weakness, while GBP/USD falls amid geopolitical tensions and U.S. tech stocks face pressure from disappointing earnings.

16 de jul. de 2026, 23:46 UTC

Social Media

Shares of Electronic Arts Inc are lower in after-market trading, reflecting a decline from earlier gains. Upcoming EA SPORTS FC 27 release is drawing attention.

16 de jul. de 2026, 23:46 UTC

News

Paychex declared a quarterly dividend of $1.19 per share, payable August 28, contributing to positive sentiment as shares rise in after-market trading.

16 de jul. de 2026, 23:46 UTC

Cintas Corp shares are higher in after-market hours. Broader market sentiment may be supported by recent labor market strength and modest retail sales growth.

16 de jul. de 2026, 23:46 UTC

ETF Constituents

News

Correlated Moves

Vanguard Growth ETF declines after-hours, impacted by Netflix's drop and broader Nasdaq 100 downturn amid rising inflation concerns and central bank comments.

16 de jul. de 2026, 23:46 UTC

American Airlines Group Inc. shares are lower in after-market trading, reflecting routine fluctuations and remaining below the 20-day moving average.

16 de jul. de 2026, 23:42 UTC

Cisco shares traded higher during after-market hours, reflecting internal dynamics. The stock's activity remained routine amid broader declines in major technology stocks.

16 de jul. de 2026, 23:41 UTC

Gilead Sciences Inc. shares moved higher in after-market trading, remaining above their 20-day moving average following three consecutive daily gains.

16 de jul. de 2026, 23:41 UTC

Lululemon shares declined in after-market trading, continuing a downward trend since Thursday's close amid weakness in major technology stocks.

16 de jul. de 2026, 23:41 UTC

News

Correlated Moves

Lam Research Corp shares are lower in after-market trading amid a sector-wide selloff following TSMC's capital expenditure announcement and bearish sentiment from options traders.

16 de jul. de 2026, 23:41 UTC

Correlated Moves

KLA Corp shares are lower in after-market hours, reflecting broader market declines amid weakness in major technology stocks and renewed semiconductor sector volatility.

16 de jul. de 2026, 23:41 UTC

ETF Constituents

Macro News

Correlated Moves

Financial Select Sector SPDR Fund trades lower in after-market hours amid broader market decline and rising tensions between the U.S. and Iran.

16 de jul. de 2026, 23:41 UTC

Trip.com Group Ltd shares are lower in after-market hours amid broader market declines, particularly in technology stocks and heightened economic uncertainty.

16 de jul. de 2026, 23:41 UTC

Baidu Inc. shares are trading lower in after-market hours, reflecting broader market declines amid volatility in the semiconductor sector and geopolitical tensions.

16 de jul. de 2026, 23:41 UTC

JD.Com Inc. shares are higher in after-market trading, supported by gains in the Broadline Retail sub-sector. The stock remains above its 20-day moving average.

16 de jul. de 2026, 23:41 UTC

Correlated Moves

Analog Devices Inc remains unchanged in after-market trading amid declines in the Nasdaq 100 Index and weakness among major technology stocks.

16 de jul. de 2026, 23:41 UTC

Macro News

Correlated Moves

Ethereum is trading lower as U.S. markets decline amid technology sector weakness and rising geopolitical tensions, impacting global sentiment in cryptocurrencies.

16 de jul. de 2026, 23:41 UTC

Macro News

Correlated Moves

Bitcoin declines amid rising U.S.-Iran tensions and market volatility. The Crypto Fear & Greed Index shows extreme fear among investors, contributing to uncertainty.

16 de jul. de 2026, 23:41 UTC

Booking Holdings Inc. shares are higher in after-market trading, maintaining levels above the 20-day moving average amid slight fluctuations since Thursday's close.

16 de jul. de 2026, 23:36 UTC

Ross Stores Inc. shares declined in after-market trading amid weakness in major technology stocks. The asset is lower since Thursday's close.

Comparação entre Pares

Variação de preço

Corvus Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

111.8% parte superior

Previsão para 12 meses

Média 31.6 USD 111.8%

Máximo 40 USD

Mínimo 27 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Corvus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Corvus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.